Introduction {#s1}
============

Breast cancer (OMIM: 114480) is the most common malignancy affecting female population worldwide. Despite early detection and improved understanding of molecular mechanisms of this disease, it is still the second leading cause of cancer death in women [@pone.0101740-Ferlay1].

Multidrug resistance (MDR) represents a major obstacle to successful therapy of tumors. MDR was first described in 1970 [@pone.0101740-Biedler1] as a cross-resistance to structurally and functionally different anticancer drugs. Most MDR is caused by enhanced expression of membrane-bound ATP-Binding Cassette (ABC) transporters [@pone.0101740-Szakacs1], [@pone.0101740-Ferguson1]. ABC transporters pump drugs outside of the cells into the extracellular space, thus reducing their cytotoxic effect [@pone.0101740-Liscovitch1]--[@pone.0101740-Akan1].

Multidrug resistance-associated protein 1 (MRP1/ABCC1, OMIM: 158343) was the first identified member of the ABCC subfamily [@pone.0101740-Cole1]. *ABCC1* gene is located on the 16^th^ chromosome at position p13.11, is approximately 200 kb long, comprises 31 exons, and encodes 190 kDa membrane protein comprising 1531 amino acids [@pone.0101740-Grant1]. ABCC1 transports a number of physiological substrates (glutathione, leucotrienes, prostaglandins, etc.) and xenobiotics including anticancer drugs (anthracyclines, taxanes, methotrexate, *Vinca* alkaloids, camptothecins, etc.) [@pone.0101740-Cole2]. The involvement of ABCC1 in the resistance to chemotherapy has been reported in various types of solid tumors [@pone.0101740-Hipfner1].

A recent tissue microarray study has concluded that high ABCC1 protein expression is a negative prognostic marker as it has been found in highly aggressive molecular subtypes of breast carcinoma [@pone.0101740-Yamada1]. Significant overexpression of ABCC1 transcript in both pre-chemotherapy (n = 100) and post-chemotherapy (n = 68) tumors compared with adjacent non-neoplastic tissues from breast carcinoma patients and associations of intratumoral transcript levels with tumor grade and expression of estrogen receptor, proliferative marker Ki67, and p53 protein have been recently reported [@pone.0101740-Hlav1].

A high number of single nucleotide polymorphisms (SNPs) in *ABCC1* have been identified in different human populations and their haplotypes were examined [@pone.0101740-Conrad1], [@pone.0101740-Oselin1]. *ABCC1* has high haplotype diversity with significant differences across ethnic groups [@pone.0101740-Wang1]. Very recently convincing association between rs4148350, rs45511401, and rs246221 SNPs in *ABCC1* and risk of febrile neutropenia in breast cancer patients treated by 5-fluorouracil, epirubicin and cyclophosphamide (FEC regimen) has been shown [@pone.0101740-Vulsteke1]. Several studies suggested *in vitro* functional effects of SNPs in *ABCC1*. For instance, Gly671Val (dbSNP: rs45511401) SNP located near the nucleotide binding domain 1 (NBD1, [**Figure 1**](#pone-0101740-g001){ref-type="fig"}) which is important for the ATPase activity was associated with reduced levels of ABCC1 transcript [@pone.0101740-Conrad1]. Serine at position 433 (rs60782127) significantly increased the resistance to doxorubicin [@pone.0101740-Conrad2] whereas serine at position 43 (rs41395947) enhanced expression and altered ABCC1 protein trafficking to the plasma membrane [@pone.0101740-Leslie1]. Moreover, several *ABCC1* SNPs including Arg723Gln (rs4148356) located between the Walker A and B motifs in NBD1 have been shown to affect the resistance to a number of anticancer drugs [@pone.0101740-Yin1].

![Schematic representation of functional domains of ABCC1.\
Figure depicts functional domains of ABCC1 protein (A) and important structural motifs within NBD1 (B). Data modified from NCBI's Conserved Domain Database (CDD) [@pone.0101740-MarchlerBauer1].](pone.0101740.g001){#pone-0101740-g001}

The present study investigated the effect of tagged haplotype of the *ABCC1* gene covering NBD1 with adjacent sequences at ABCC1 transcript level in tumor and non-neoplastic tissues from breast cancer patients. In addition, we also addressed the prognostic and predictive significance of genetic variability of *ABCC1*.

Materials and Methods {#s2}
=====================

Material {#s2a}
--------

General chemicals, histopaque (Ficoll), phenol, chloroform, RNase A, proteinase K, *Taq* polymerase, and histidine were purchased from Sigma-Aldrich (Prague, Czech Republic). Deoxynucleotides (dNTPs) for PCR and molecular weight standards for electrophoresis (ΦX174DNA/HaeIII digest) were products of New England Biolabs, Inc. (Ipswich, MA). Ultrapure agarose was supplied by Life Technologies (Prague, Czech Republic).

Patients {#s2b}
--------

The study included a total of 540 breast cancer patients (C50 according to ICD-10) of Caucasian origin diagnosed in Motol Faculty Hospital, Institute for the Care for Mother and Child, BIOLAB Praha k.s., and Faculty Hospital Kralovske Vinohrady in Prague, Czech Republic between February 2000 and December 2010 (for study flow diagram see [**Figure S1 in File S1**](#pone.0101740.s001){ref-type="supplementary-material"}). Blood samples were available from all patients. Tumor tissue samples were collected during the primary surgery from subgroups of patients. First subgroup of patients (n = 60) underwent preoperative neoadjuvant chemotherapy regimens based on 5-fluorouracil/anthracyclines/cyclophosphamide (FAC or FEC) and/or taxanes. The second subgroup was treated by adjuvant chemotherapy and/or hormonal therapy after surgery (n = 89). Paired samples of adjacent non-neoplastic tissues as controls were available from 67 patients. In the whole set, patients with metastatic disease treated by first line palliative therapy were also included (for all treatments see [**Table S1 in File S1**](#pone.0101740.s001){ref-type="supplementary-material"}). Collection and pathological processing of tissue samples and retrieval of data was performed as described before [@pone.0101740-Hlav1], [@pone.0101740-Brynychov1]. Expression of receptors for estrogen (ER) and progesterone (PR) was evaluated as positive when at least 10% of cell nuclei showed staining by routine immunohistochemistry. HER2 (ERBB2, OMIM: 164870) status was defined as positive in samples with immunohistochemical score 2+ or 3+ confirmed by SISH analysis. For expression of the p53 (OMIM: 191170) protein, 50% cut off was used (negative \<50% vs. positive ≥50%, see [Material and Methods S1 and References S1 in File S1](#pone.0101740.s001){ref-type="supplementary-material"}). Patients were experimentally divided into groups according to molecular subtypes of their tumors (Luminal A = ER+/HER2− and grade 1 or 2, Luminal B/HER2- = ER+/HER2− and grade 3, Luminal B/HER2+ = ER+/HER2+, HER2+ = ER−/HER2+, and triple negative = ER−/PR−/HER2−) according to [@pone.0101740-Goldhirsch1]. All patients after primary chemotherapy and surgery were followed for local or distant relapse or in the case of palliative setting for disease progression by regular visits every 3 months during the first 3 years, twice a year during the next 2 years and yearly then after. During the visits mammography, chest X ray, skeletal survey, and abdominal ultrasound was performed yearly and clinical examination together with tumor markers (CEA and CA 15-3) was performed during every visit. In the case of clinical uncertainty, additional tests and examinations were performed to rule out possible disease relapse or progression.

Ethics statement {#s2c}
----------------

All patients were asked to read and sign an informed consent and the study was approved by the Ethical Commission of the National Institute of Public Health in Prague.

DNA extraction {#s2d}
--------------

Blood samples were collected during the diagnostic procedures using tubes with K~3~EDTA anticoagulant. Genomic DNA was isolated from human peripheral blood lymphocytes by the standard phenol/chloroform extraction and ethanol precipitation method [@pone.0101740-Topic1]. DNA samples were stored in aliquots at −20°C prior to analysis.

ABCC1 genotyping {#s2e}
----------------

DNA sequence covering coding exons 15--19 (NBD1), interspersed introns, and sequences surrounding both 5′- and 3′-untranslated regions (Chr16∶16,076,000--16,091,000, NCBI Build 36.3 version) were analyzed by HaploView v4.2 program [@pone.0101740-Barrett1]. Together nine SNPs tagging common haplotypes at r^2^\>0.8 and minor allele frequency (MAF)\>0.05 in HapMap CEU sample with minimally 75% genotype data were identified. The *ABCC1* region containing eight selected SNPs (rs35623, rs4148351, rs35626, rs11075295, rs3851711, rs3888565, rs35625, and rs4148350) was then divided into four regions. Inside of these regions, we also analyzed additional four SNPs (rs35628, rs11866794, rs4148353, and rs4148356). All analyzed SNPs are characterized in [**Table S2 in File S1**](#pone.0101740.s001){ref-type="supplementary-material"}. For each region pair of forward and reverse primers with M13 sequence adaptors was designed using the Primer3 software [@pone.0101740-Untergrasser1]. Oligonucleotide primers were synthesized by Generi Biotech (Hradec Kralove, Czech Republic). Twelve SNPs were then determined by direct sequencing. PCR products were generated using 50 ng of genomic DNA in a 25 µl final volume containing 2.5 µl of 10× reaction buffer consisting of 0.8 (region 1) or 1.6 mM MgCl~2~ (regions 2--4), 0.25 mM dNTPs, 0.2 µM of each primer, and 0.5 µl of *Taq* DNA polymerase, 1 U/µl (all chemicals except for dNTPs from Top-Bio, Vestec, Czech Republic). Primer sequences and optimized conditions for PCR cycling are specified in [**Table S3 in File S1**](#pone.0101740.s001){ref-type="supplementary-material"}. The PCR products were resolved and analyzed on 2% agarose gel containing ethidium bromide and visualized by ultraviolet light. All samples containing the PCR products were then sequenced by using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technologies) with 5 ng of PCR product and 2 pmol of universal M13 sequencing primer in a 10 µl final reaction volume. PCR conditions for sequencing reactions were as recommended by the producer (Life Technologies). Separate sequencing reaction included a control template pGEM-3Zf(+) under the same conditions as above. Sequencing products were purified by EDTA/sodium acetate/ethanol precipitation. DNA sequencing was performed on Applied Biosystems 3130×L Genetic Analyzer and the results were evaluated by Sequencing Analysis Software v5.2 (Life Technologies). About 10% of samples were re-sequenced with 100% conformity of the results.

ABCC1 gene expression {#s2f}
---------------------

Total RNA was isolated from frozen tissues, stored, and characterized as described [@pone.0101740-Brynychov1]. cDNA was synthesized using 0.5 µg of total RNA and random hexamer primers with the help of RevertAid™ First Strand cDNA Synthesis Kit (MBI Fermentas, Vilnius, Lithuania). Quality of cDNA in terms of DNA contamination was confirmed by PCR amplification of *ubiquitin C* [@pone.0101740-Soucek1]. Quantitative real-time PCR (qPCR) of ABCC1 and reference genes EIF2B1 (OMIM:606686), MRPL19 (OMIM:611832), IPO8 (OMIM:605600), and UBB (OMIM:191339) was performed in RotorGene 6000 (Corbett Research, Sydney, Australia) as described [@pone.0101740-Hlav1]. Reference genes for data normalization were selected using software programs geNorm (version 3.5) and NormFinder (version 19) (see [File S1](#pone.0101740.s001){ref-type="supplementary-material"}). The qPCR study design adhered to the MIQE Guidelines (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) [@pone.0101740-Bustin1].

Statistical analyses {#s2g}
--------------------

The following differences in distribution of genotypes were evaluated: wild type *vs.* minor allele carrier (dominant model) and rare genotype carrier *vs*. wild type allele carrier (recessive model). The additive model was also tested. Haplotypes were evaluated using HaploView software program version 4.2 [@pone.0101740-Barrett1]; phasing of haplotypes prior to a block selection was done using the E-M algorithm and the block selection was based on confidence intervals [@pone.0101740-Gabriel1]. Associations between categorized values as genotypes or haplotypes and clinical-pathological data were analyzed using the two-sided Fisher's Exact test. Clinical and pathological variables included menopausal status (pre- *vs.* post- or perimenopausal), stage (stage I *vs*. stage II--IV), tumor size (pT1 *vs*. pT2-4), lymph node metastasis (pN0 *vs.* pN1-3), histological type (invasive ductal *vs.* other invasive carcinoma) and grade (grade 1 *vs.* grade 2 or 3), expression of ER, PR, and HER2 (negative *vs.* positive), p53 expression (negative *vs.* positive), and molecular subtypes (triple negative *vs*. other and luminal A *vs.* luminal B/HER2−). Differences in transcript levels or age between patients divided by categorized data as genotypes, haplotypes, and clinical-pathological data were evaluated by nonparametric tests (Mann-Whitney, Kruskal-Wallis). Disease-free survival (DFS) was evaluated by the Kaplan-Meier method and the Breslow test was used for evaluation of the compared groups of patients. Multiparametric analysis was then performed by the Cox proportional hazards model. DFS was defined as the time elapsed between surgical treatment and disease progression or death from any cause. Patients lost to follow-up and patients with stage IV disease were excluded from DFS analyses. The results were evaluated by the statistical program SPSS v15.0 (SPSS, Chicago, IL). All p-values are departures from two-sided tests. A p-value of less than 0.05 was considered statistically significant. The correction for false discovery rate (FDR) was applied according to Benjamini and Hochberg [@pone.0101740-Benjamini1] and q-values are provided for each comparison. The functional relevance of examined SNPs was analyzed *in silico* by Regulome DB (<http://regulome.stanford.edu>), PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2>), and SIFT (<http://sift.jcvi.org>) programs. Genetic variants and their observed associations with clinical and functional phenotype were submitted to NCBI (The National Center for Biotechnology Information) ClinVar database (<http://www.ncbi.nlm.nih.gov/clinvar>).

Results {#s3}
=======

Patients' characteristics {#s3a}
-------------------------

Clinical characteristics of patients are presented in [**Table 1**](#pone-0101740-t001){ref-type="table"}.

10.1371/journal.pone.0101740.t001

###### Clinical-pathological characteristics of patients.

![](pone.0101740.t001){#pone-0101740-t001-1}

  Characteristics                        Type            n     \%
  ------------------------------ --------------------- ----- -------
  **Average age at diagnosis**        58±11 years       540   100.0
  **Menopausal status**              premenopausal      119   22.2
                                    postmenopausal      416   77.8
                                     not assessed        5     --
  **Histological tumor type**       invasive ductal     400   76.0
                                  other invasive type   126   24.0
                                     not assessed       14     --
  **Histological grade (G)**              GI            103   22.1
                                          GII           238   51.1
                                         GIII           125   26.8
                                          Gx            74     --
  **Stage (S)**                           SI            223   44.7
                                          SII           211   42.3
                                         SIII           51    10.2
                                          SIV           14     2.8
                                     not assessed       41     --
  **pT**                                  pT1           316   61.5
                                          pT2           161   31.3
                                          pT3           17     3.3
                                          pT4           20     3.9
                                          pTx           26     --
  **pN**                                  pN0           316   62.0
                                          pN1           158   31.0
                                          pN2           25     4.9
                                          pN3           11     2.2
                                          pNx           30     --
  **cM**                                  cM0           501   97.1
                                          cM1           15     2.9
                                          cMx           24     --
  **Expression of estrogen**           positive         393   74.9
  **receptor**                         negative         132   25.1
                                     not assessed       15     --
  **Expression of**                    positive         385   73.8
  **progesterone receptor**            negative         137   26.2
                                     not assessed       18     --
  **Expression/amplification**         positive         120   25.2
  **of HER2**                          negative         357   74.8
                                     not assessed       63     --
  **p53 protein expression**           positive         35    29.9
                                       negative         82    70.1
                                     not assessed       423    --

Distribution of genotypes and haplotypes {#s3b}
----------------------------------------

Twelve SNPs selected with the help of HaploView v4.2 pairwise tagging algorithm of the region including NBD1 and surrounding sequences of *ABCC1* were genotyped in 540 breast carcinoma patients. The rate of missing genotype data due to DNA of insufficient quality or quantity did not exceed 3.5% in particular SNPs.

The distribution of all analyzed SNPs (rs35623, rs4148351, rs35626, rs11075295, rs3851711, rs3888565, rs35625, rs4148350, rs35628, rs11866794, rs4148353, and rs4148356) is presented in [**Table 2**](#pone-0101740-t002){ref-type="table"}. Genotype distribution of the studied SNPs did not significantly deviate from the Hardy-Weinberg equilibrium (p\>0.01). MAFs of these SNPs did not substantially differ from HapMap-CEU population (n = 226) available in dbSNP. Experimental data were reanalyzed by HaploView v4.2 and LD' values and haplotype blocks were predicted ([**Figure 2**](#pone-0101740-g002){ref-type="fig"}). This analysis revealed several SNP-SNP combinations (diplotypes, [**Table 3**](#pone-0101740-t003){ref-type="table"}). To reach reasonable statistical power the most frequent diplotypes with n\>40 (highlighted in [**Table 3**](#pone-0101740-t003){ref-type="table"}) were further analyzed.

![Haplotype analysis of *ABCC1* SNPs.\
Figure indicates linkage disequilibrium plot (A) and three blocks comprising of SNP diplotypes (B) predicted from experimental data obtained in the present study. The likelihood of linkage of two tested SNPs increases from white to red color (A). Population frequency of diplotypes and connections from one diplotype block to the next one are shown (B). Analysis was performed by HaploView v4.2 program.](pone.0101740.g002){#pone-0101740-g002}

10.1371/journal.pone.0101740.t002

###### Distribution of *ABCC1* SNPs and allele frequencies in breast cancer patients.

![](pone.0101740.t002){#pone-0101740-t002-2}

  SNP ID            Localization   Genotype   distribution   Missing   Type[\*](#nt102){ref-type="table-fn"}   MAF[\#](#nt103){ref-type="table-fn"}  
  ---------------- -------------- ---------- -------------- --------- --------------------------------------- -------------------------------------- ----------
  **rs35623**        intron 15        GG          422         79.5                    9 (1.7)                                   NC                    T (0.11)
                                      GT          100         18.8                                                                                   
                                      TT           9           1.7                                                                                   
  **rs35625**        intron 15        TT          217         40.9                    9 (1.7)                                   NC                    C (0.37)
                                      TC          234         44.1                                                                                   
                                      CC           80         15.1                                                                                   
  **rs11866794**     intron 15        GG          415         78.2                    9 (1.7)                                   NC                    C (0.12)
                                      GC          108         20.3                                                                                   
                                      CC           8           1.5                                                                                   
  **rs4148350**      intron 15        GG          466         89.3                   18 (3.3)                                   NC                    T (0.06)
                                      GT           52         10.0                                                                                   
                                      TT           4           0.8                                                                                   
  **rs4148351**      intron 15        CC          416         79.5                   17 (3.1)                                   NC                    T (0.11)
                                      CT           97         18.6                                                                                   
                                      TT           10          1.9                                                                                   
  **rs35626**        intron 16        GG          261         50.1                   19 (3.5)                                   NC                    T (0.29)
                                      GT          220         42.2                                                                                   
                                      TT           40          7.7                                                                                   
  **rs35628**        intron 16        AA          441         84.0                   15 (2.8)                                   NC                    G (0.09)
                                      AG           77         14.7                                                                                   
                                      GG           7           1.3                                                                                   
  **rs4148353**      intron 16        GG          426         81.3                   16 (3.0)                                   NC                    T (0.10)
                                      GT           91         17.4                                                                                   
                                      TT           7           1.3                                                                                   
  **rs4148356**       exon 17         GG          516         96.3                    4 (0.7)                                 R723Q                   A (0.02)
                                      GA           19          3.5                                                                                   
                                      AA           1           0.2                                                                                   
  **rs11075295**     intron 17        AA          375         69.8                    3 (0.6)                                   NC                    G (0.17)
                                      AG          139         25.9                                                                                   
                                      GG           23          4.3                                                                                   
  **rs3888565**      intron 18        GG          380         70.6                    2 (0.4)                                   NC                    A (0.17)
                                      GA          134         24.9                                                                                   
                                      AA           24          4.5                                                                                   
  **rs3851711**      intron 18        TT          151         28.1                    2 (0.4)                                   NC                    G (0.49)
                                      TC          248         46.1                                                                                   
                                      CC          139         25.8                                                                                   

Footnotes:

\*NC = non-coding.

MAF = minor allele frequency.

10.1371/journal.pone.0101740.t003

###### Distribution of *ABCC1* diplotypes predicted by HaploView v4.2.

![](pone.0101740.t003){#pone-0101740-t003-3}

  Diplotype 1             rs11866794              
  ----------------- ---- ------------ ----------- --------
  rs35625            TT    **215**         1         1
                     TC    **161**      **73**       0
                     CC       39          34         7
  **Diplotype 2**                       rs35626   
                              GG          GT         TT
  rs4148351          CC    **258**      **140**      17
                     CT       2         **80**       14
                     TT       1            0         9
  **Diplotype 3**                      rs3851711  
                              TT          TC         CC
  rs3888565          GG    **151**      **163**    **66**
                     GA       0         **81**     **53**
                     AA       0            4         20

Numbers of patients with combinations of diplotypes presented.

The most frequent diplotypes used for statistical analyses in bold.

Associations of ABCC1 SNPs and diplotypes with transcript levels {#s3c}
----------------------------------------------------------------

The ABCC1 transcript level was previously assessed in tumors and non-neoplastic control tissues from breast cancer patients [@pone.0101740-Hlav1]. A subset of these patients with complete genotype data was included into this study (n = 149) and associations between genotypes, predicted diplotypes, and transcript levels were analyzed by Mann-Whitney or Kruskal-Wallis tests. Associations of all SNPs and frequent diplotypes with expression levels were analyzed but to retain concise style only significant results are reported ([**Table 4**](#pone-0101740-t004){ref-type="table"} and [**Figure 3**](#pone-0101740-g003){ref-type="fig"}). Tumors from carriers of the wild type genotype in rs35623 or rs35628 expressed significantly lower ABCC1 transcript levels than those with the minor allele (p = 0.003 and p = 0.004, respectively; q = 0.008, both significant; [**Table 4**](#pone-0101740-t004){ref-type="table"} and [**Figures 3A, B**](#pone-0101740-g003){ref-type="fig"}). A significant upward trend in the ABCC1 transcript level in the order CT-GT\>CC-GT\>CC-GG (p = 0.023; q = 0.017, non-significant; [**Table 4**](#pone-0101740-t004){ref-type="table"} and [**Figure 3C**](#pone-0101740-g003){ref-type="fig"}) for the rs35626-rs4148351 diplotype was observed. Non-neoplastic control tissues from carriers of the wild type genotype in rs11866794 expressed lower ABCC1 transcript levels than those with the minor allele (p = 0.017; q = 0.004, non-significant; [**Table 4**](#pone-0101740-t004){ref-type="table"} and [**Figure 3D**](#pone-0101740-g003){ref-type="fig"}). The rs4148356 SNP was predicted to be benign with a score of 0.014 by PolyPhen-2 and tolerated with a score 0.30 by SIFT programs. From synonymous SNPs, rs35626 was classified as likely to affect binding and linked to expression of a gene target (score 1f), rs35625, and rs11866794 as likely to affect binding (2c) by the Regulome DB program. The rest of SNPs was classified as having minimal binding evidence (4--6; [**Table S4 in File S1**](#pone.0101740.s001){ref-type="supplementary-material"}).

![Significant associations between transcript levels and polymorphisms in *ABCC1*.\
All SNPs and frequent diplotypes were analyzed but to retain concise style only significant associations are reported.](pone.0101740.g003){#pone-0101740-g003}

10.1371/journal.pone.0101740.t004

###### Significant associations of *ABCC1* polymorphisms with expression levels.

![](pone.0101740.t004){#pone-0101740-t004-4}

  Genotype                               n        Normalized ABCC1 expression in tumors (Mean Rank)[\*](#nt108){ref-type="table-fn"}
  ----------------------------------- ------- -------------------------------------------------------------------------------------------
  **rs35623**                                 
  GG                                    116                                              78.1
  GT or TT                              29                                               52.5
  Missing                                4                                                --
  p-value                                                               0.003[\#](#nt109){ref-type="table-fn"}
  **rs35628**                                 
  AA                                    117                                              73.6
  AG or GG                              21                                               46.8
  Missing                               11                                                --
  p-value                                                               0.004[\#](#nt109){ref-type="table-fn"}
  **Diplotype 2 rs35626-rs4148351**           
  CC-GG                                 66                                               69.3
  CC-GT                                 38                                               60.0
  CT-GT                                 20                                               44.7
  Missing                               25                                                --
  p-value                                                                                0.023
  **Genotype**                         **n**   **Normalized ABCC1 expression in controls (Mean Rank)** [\*](#nt108){ref-type="table-fn"}
  **rs11866794**                              
  GG                                    48                                               36.9
  GC or CC                              18                                               24.4
  Missing                                1                                                --
  p-value                                                                                0.017

All SNPs and frequent diplotypes were analyzed but to retain concise style only significant associations are reported.

Footnotes:

\*Analyzed by Mann-Whitney test. The higher is the rank the lower is the normalized expression ABCC1/reference genes.

Result passed FDR analysis for multiple testing [@pone.0101740-Benjamini1].

Associations between clinical characteristics, therapy outcome, and ABCC1 SNPs and diplotypes {#s3d}
---------------------------------------------------------------------------------------------

Associations of all SNPs and frequent diplotypes with clinical data were analyzed but to retain concise style only significant results are reported ([**Table 5**](#pone-0101740-t005){ref-type="table"}). The *ABCC1* SNP rs3888565 was significantly associated with expression of estrogen receptor ([**Table 5**](#pone-0101740-t005){ref-type="table"}). Carriers of the AA genotype had more frequently tumors without ER expression than carriers of the G allele (p = 0.003; q = 0.004, significant). Moreover, G allele in this SNP was associated with triple-negative disease exhibiting the worst prognosis of all molecular subtypes of breast carcinoma (p = 0.008; q = 0.004, non-significant). Regarding rs4148350, patients with stages II--IV (advanced disease) or lymph nodes affected by metastasis had a greater incidence of the T allele than those with early stage I or metastasis-free lymph nodes (p = 0.005 and p = 0.028, respectively; q = 0.004 and q = 0.008, both non-significant). Similarly, patients with HER2-positive tumors carried more frequently the T allele in rs4148350 than those without HER2 expression (p = 0.014; q = 0.004, non-significant). The T allele in rs4148353 also predisposed patients to tumors with ER expression in comparison with wild type carriers (p = 0.049; q = 0.004, non-significant). On the other hand, tumors of the T allele carriers in respect to rs4148353 were usually HER2-negative (p = 0.001; q = 0.004, significant; [**Table 5**](#pone-0101740-t005){ref-type="table"}). Advanced stages II--IV, similarly as tumors with grades 2 or 3 occurred more frequently in carriers of the C allele in rs35625 than in those with the wild type TT (p = 0.040, p = 0.029, respectively; q = 0.004 and q = 0.008, both non-significant). Carriers of the C allele in rs3851711 had more frequently tumors of histological type other than ductal and exhibited more frequently triple-negative molecular subtype histology than those with the TT genotype (p = 0.040 and p = 0.039, respectively; q = 0.004 and q = 0.008, both non-significant).

10.1371/journal.pone.0101740.t005

###### Significant associations of *ABCC1* polymorphisms with clinical data.

![](pone.0101740.t005){#pone-0101740-t005-5}

  Characteristics          rs3888565       p-value[\*](#nt112){ref-type="table-fn"}     
  --------------------- --------------- ----------------------------------------------- ----------------------------------------
  ER negative                 119                             13                        
  ER positive                 380                             10                         0.003[\#](#nt113){ref-type="table-fn"}
  Triple negative             49                               7                        
  Other subtype               465                             17                                         0.008
  **Characteristics**    **rs4148350**   **p-value** [\*](#nt112){ref-type="table-fn"}  
                            **GG**                         **GT/TT**                    
  Stage II--IV                229                             40                        
  Stage I                     199                             14                                         0.005
  pN1-3                       162                             29                        
  pN0                         276                             26                                         0.028
  HER2 negative               315                             29                        
  HER2 positive               96                              20                                         0.014
  **Characteristics**    **rs4148353**   **p-value** [\*](#nt112){ref-type="table-fn"}  
                            **GG**                         **GT/TT**                    
  ER negative                 111                             16                        
  ER positive                 304                             78                                         0.049
  HER2 negative               270                             76                        
  HER2 positive               106                             10                         0.001[\#](#nt113){ref-type="table-fn"}
  **Characteristics**     **rs35625**    **p-value** [\*](#nt112){ref-type="table-fn"}  
                            **TT**                         **TC/CC**                    
  Grade 2 or 3                133                             222                       
  Grade 1                     51                              51                                         0.029
  Stage II--IV                101                             46                        
  Stage I                     102                             26                                         0.040
  **Characteristics**    **rs3851711**   **p-value** [\*](#nt112){ref-type="table-fn"}  
                            **TT**                         **TC/CC**                    
  Ductal type                 121                             277                       
  Other type                  26                              100                                        0.040
  Triple-negative             11                              21                        
  Other subtype               140                             118                                        0.039

All SNPs and frequent diplotypes were analyzed but to retain concise style only significant associations are reported.

Footnotes:

\*Analyzed by two-sided Fisher's Exact test.

Result passed FDR analysis for multiple testing [@pone.0101740-Benjamini1].

No association between age at diagnosis, menopausal status, tumor size, expression of progesterone receptor, and p53 and the SNPs followed was found (results not shown). Large tumor size (pT2-4), presence of lymph node metastasis (pN1-3), lack of expression of hormonal receptors (ER and PR), and triple-negative molecular subtype were significant predictors of poor prognosis, i.e. short DFS in the set of chemotherapy-treated patients (p\<0.001, p = 0.001, p = 0.011, p = 0.001, and p = 0.003, respectively). Large tumor size (pT2-4), presence of lymph node metastasis (pN1-3), and lack of expression of PR were significant predictors of poor prognosis, i.e. short DFS in the set of hormonal therapy-treated patients (p = 0.001, p\<0.001, and p = 0.031, respectively). Chemotherapy-treated patients carrying T allele in the rs4148353 SNP had longer DFS than those with wild type GG genotype in univariate analysis (n = 271, p = 0.043; [**Figure 4A**](#pone-0101740-g004){ref-type="fig"}). On the other hand, hormonal therapy-treated patients with the wild type AA genotype in the rs35628 had longer DFS than patients carrying the G allele (n = 353, p = 0.012; [**Figure 4B**](#pone-0101740-g004){ref-type="fig"}). Multivariate analysis using the Cox regression hazard model with pT, pN, ER, and PR expression, triple-negative molecular subtype, and individual SNPs has not confirmed association with DFS for rs4148353 (n = 252, p = 0.116). However, for rs35628 the association observed in univariate model remained significant in multivariate model with pT, pN, and PR expression (n = 323, p = 0.008). Survival analysis was not corrected for multiple testing.

![Significant associations between DFS of patients with breast carcinoma and SNPs in *ABCC1*.\
Kaplan-Meier survival curves for patients treated by chemotherapy (A) and hormonal therapy (B) were analyzed by Breslow test. In part A, dashed line represents DFS of patients with the GG genotype in rs4148353, while solid line indicates that of patients with the T allele. In part B, dashed line represents DFS of patients with the G allele in rs35628 and solid line DFS of those with the AA genotype. All SNPs have been analyzed but to retain concise style only significant associations are reported.](pone.0101740.g004){#pone-0101740-g004}

Discussion {#s4}
==========

Multidrug resistance frequently causes cancer treatment failure. Numerous *in vitro* and *in vivo* data revealed that multidrug resistance is often due to enhanced expression ABC transporters [@pone.0101740-Szakcs1]. Thus, in depth analysis of ABC transporters appears inevitable for individualization of treatment.

The multidrug resistance-associated protein 1 encoded by the *ABCC1* gene is one of the most studied ABC transporters. Very recently, we demonstrated significant overexpression of ABCC1 transcript in tumors compared to adjacent non-neoplastic tissues from breast cancer patients and suggested its intratumoral levels as potential modifiers of breast carcinoma progression [@pone.0101740-Hlav1]. Another contemporary study has suggested that a high ABCC1 protein expression is a negative prognostic marker, as it has been found in highly aggressive molecular subtypes of breast carcinoma [@pone.0101740-Yamada1]. Despite already accumulated knowledge on ABCC1 there are significant gaps in understanding its role in cancer therapy and prognosis which preclude clinical applications.

NBD1 of ABCC1 contains several functional motifs, ATP-binding site, Walker A/P-loop, Q-loop/lid, ABC transporter signature, Walker B, D-loop, and H-loop/switch ([**Figure 1**](#pone-0101740-g001){ref-type="fig"}). Unlike most ABCC proteins, NBD1 of ABCC1 binds ATP with high affinity but has low hydrolytic activity, while the reverse is true of NBD2 [@pone.0101740-Gao1]. Besides this functional asymmetry, it seems obvious that NBD1 and NBD2 cooperate together and with surrounding transmembrane cytoplasmic loops may influence substrate selectivity and the proper assembly and trafficking of ABCC1 to the plasma membrane [@pone.0101740-Qin1], [@pone.0101740-Iram1]. Moreover, very recently, virtual screening of X-ray crystal structure of ABCC1 NBD1 [@pone.0101740-Ramaen1] revealed that about 5% of the National Cancer Institute compounds possessed lower docking scores than ATP in ABCC1 NBD1 and it has been suggested that the compounds identified may be potential inhibitors of ABCC1 and require further pharmacological analysis [@pone.0101740-Rungsardthong1]. Apparently, the role of ABCC1 as predictive biomarker and potential drug target in human cancers raises further interest.

The present study addressed yet unexplored associations between genetic variability in NBD1 and adjacent sequences of *ABCC1* and clinical course of breast cancer. Further, it evaluated relations between genotype and phenotype represented by transcript levels in tissues of breast cancer patients.

Analogously with the ABCB1/P-glycoprotein [@pone.0101740-Vaclavikova1], in the present study, we have observed associations between genetic variability in *ABCC1* and its transcript levels in tissues from breast cancer patients. Carriers of the wild type genotype in rs35623 or rs35628 SNPs had significantly lower ABCC1 levels in their tumors than the rest of patients, suggesting their potential as predictors of treatment outcomes. The association of the rare CT-GT diplotype rs35626-rs4148351 with ABCC1 transcript levels observed in the uncorrected analysis has not passed the FDR test and should be replicated on a larger sample size.

The analysis of associations between *ABCC1* SNPs and transcript levels could be confounded by the fact that some patients received pre-operative chemotherapy. Some ABC transporters may be induced by chemotherapy [@pone.0101740-Kim1]. However, in our study the difference in ABCC1 transcript levels between post- and pre-treatment patients was non-significant (p\>0.05).

Most interestingly, the rs35628 SNP significantly influenced DFS of patients treated by hormonal therapy in both univariate and multivariate analysis. Taken together, patients with the wild type genotype AA in rs35628 SNP had lower ABCC1 levels in tumors and better survival rates after hormonal therapy than those with the G allele. Cell lines with overexpression of ABCC1 are resistant to anticancer drugs [@pone.0101740-Szakcs1] and high expression of ABCC1 protein was associated with shorter DFS [@pone.0101740-Filipits1]. The role of ABCC1 in the efflux of anticancer drugs has been recently proposed [@pone.0101740-McDonagh1], [@pone.0101740-Thorn1]. On the other hand, the intratumoral ABCC1 transcript level did not modify DFS of unselected patients (n = 88) or patients stratified according to the therapy type, referring to a more complex phenomenon [@pone.0101740-Hlav1]. We also have not found significant association between transcript and protein levels of ABCC1 (n = 30) in the previous study on independent set of patients [@pone.0101740-Hlav1].

Tamoxifen metabolites endoxifen and 4-hydroxy-tamoxifen are substrates of the ABCB1 transporter *in vitro* [@pone.0101740-Teft1], but the association of genetic variation in *ABCB1* and tamoxifen effectiveness is unknown. The role of ABCC1/MRP1 in the transport of tamoxifen, its metabolites or aromatase inhibitors also remains vastly unexplored [@pone.0101740-Kiyotani1] and thus it is currently impossible to draw any conclusive remarks from our observations in hormonally-treated breast cancer patients.

We have also found out that chemotherapy-treated carriers of the T allele in rs4148353 SNP had significantly better DFS than those with the wild type GG genotype. However, this association has not been confirmed by multivariate analysis. The association of rs4148353 with DFS could be modulated by the significant associations of this SNP with ER and mainly HER2 which were shown to be the best predictors of chemotherapy response in breast carcinoma [@pone.0101740-Lips1]. Patients carrying the T allele had higher frequency of ER-positive or HER2-negative tumors when compared with wild type carriers in the present study and the lack of expression of hormonal receptors or the triple-negative molecular subtype of breast cancer were indeed significant predictors of poor DFS.

Despite the fact that the *ABCC1* rs4148356 SNP located between the Walker A and B motifs in NBD1 has been shown to affect resistance to a number of anticancer drugs [@pone.0101740-Yin1], we did not find association of this SNP with DFS in breast cancer patients. We confirmed the previously observed lack of effect of rs4148356 (R723Q, 2168G\>A) on ABCC1 expression [@pone.0101740-Letourneau1]. Also *in silico* analyses performed by PolyPhen-2 [@pone.0101740-Adzhubei1] and SIFT [@pone.0101740-Kumar1] programs support our observations. Ten other non-synonymous SNPs leading to amino acid substitutions (Cys43Ser (G128C, rs41395947), Thr73Ile (C218T, rs41494447), Ser92Phe (C257T, rs8187844), Thr117Met (C350T, no rs number available), Arg230Gln (G689A, rs8187848), Arg633Gln (G1898A, rs112282109), Ala989Thr (G2965A, rs35529209), Cys1047Ser (G3140C, rs13337489), Arg1058Gln (G3173A, rs41410450), and Ser1512Leu (C4535T, rs369410659)) followed earlier had no effect on ABCC1 expression either, indicating that single amino acid substitutions may not necessarily influence the activity of the final protein [@pone.0101740-Letourneau1]. No significant effect of the synonymous SNPs G816A (rs2230669), T825C (rs246221), T1684C (rs35605), and G4002A (rs2230671) on ABCC1 transcript level in peripheral CD4+ cells has been observed as well [@pone.0101740-Oselin1]. From the synonymous SNPs followed by the present study, *in silico* analyses by help of Regulome DB [@pone.0101740-Boyle1] suggested that rs35625, rs35626, and rs11866794 likely affect regulation of target gene transcription.

The lack of validation study in independent sample set may be seen as limitation of the present study. By searching Catalog of Published Genome-Wide Association Studies at NHGRI ([www.genome.gov](http://www.genome.gov)) and GWAS Central ([www.gwascentral.org](http://www.gwascentral.org)) we have found no supportive data for associations between *ABCC1* SNPs with breast carcinoma survival or therapy response that could support our results. Microarray study that explored associations of transcript levels with SNP markers from the International HapMap Project in lymphoblastoid cells of 57 unrelated CEPH individuals has not observed such association(s) for ABCC1 [@pone.0101740-Cheung1].

Significant associations of non-coding SNPs with expression and clinical phenotype observed by the present study were not confirmed by *in silico* analyses or additional experimental data. This fact limits the interpretation of the results before complex functional study is completed.

In conclusion, according to our present data, SNPs rs35623 and rs35628 in non-coding regions around NBD1 may modulate ABCC1 transcript levels in breast tumors, thus contributing to a complex pattern of chemotherapy resistance by so far unknown mechanism. Associations of rs35628 and rs4148353 with DFS of breast cancer patients warrant further studies aimed at validation or disqualification of these putative prognostic markers.

Supporting Information {#s5}
======================

###### 

Contains the following files: **Material and Methods S1. References S1. Table S1:** Chemotherapy and hormonal therapy regimens. **Table S2:** Positions of the analyzed SNPs in *ABCC1.* **Table S3:** Sequencing primers and PCR conditions for assessment of polymorphisms in NBD1 of *ABCC1.* **Table S4:** *In silico* analysis of functional significance of all studied polymorphisms in NBD1 of *ABCC1.* **Figure S1:** Flow diagram of the study.

(DOC)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**Dr. Marketa Trnková is employed by a commercial company (Biolab Praha, k.s.). This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

[^2]: Conceived and designed the experiments: RV DV VP PS. Performed the experiments: TK VH RV. Analyzed the data: TK KR MT KK MA LV PS. Contributed reagents/materials/analysis tools: VP KR MT KK MA LV PV. Wrote the paper: TK RV VH DV PV PS.
